Clinical trial
A Seamless Phase 1/3, Multicenter, Single Dose Systemic Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Subjects (COMPASS)
NCT06952686 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Seamless Phase 1/3, Multicenter, Single Dose Systemic Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Subjects (COMPASS)
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- June 30, 2025
- Completion date
- March 30, 2032
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.